Category
Small Molecule CDMOs
Compare small molecule CDMOs for API synthesis, drug product formulation, and finished dosage manufacturing. Filter by chemistry capabilities, scale, and regulatory approvals.
407 companies listed
About Small Molecule Manufacturing
Small molecule manufacturing covers two distinct stages: active pharmaceutical ingredient (API) synthesis and drug product (DP) formulation. API work involves multi-step chemical synthesis, from kilo-lab through pilot-plant to commercial scale. Drug product work transforms the API into tablets, capsules, injectables, or other dosage forms.
Process chemistry is where projects succeed or fail. Look for CDMOs with strong route scouting and process optimization capabilities. A good CDMO can improve yields by 20-40% during scale-up, saving months of development time. Crystallization expertise is particularly critical for controlling polymorphic form and particle size distribution.
How does your CDMO handle potent compounds? Many oncology and hormonal APIs require OEB4 or OEB5 containment. Not every small molecule CDMO has the engineering controls for sub-microgram exposure limits. Verify containment capabilities early -- retrofitting is expensive and slow.
Companies (407)
Catalent Pharma Solution
Argentina
Catalent is a leading global CDMO trusted by pharma, biotech, and self-care companies to accelerate the development, manufacturing, and delivery of products that improve lives. With a worldwide network of facilities, advanced technologies, and deep expertise, Catalent provides integrated end-to-end solutions spanning oral dose, biologics, specialty therapies, cell and gene therapy, and clinical supply. The company partners with innovators from early-stage design through commercial manufacturing.
Small Molecule Drug ProductOral Solid DoseFormulation Development
Celltrion
South Korea
Celltrion is a major South Korean biopharmaceutical company offering CDMO services for biologics, biosimilars, and small molecules. The company operates production capacities from 1,000L to 15,000L with a 98.5% batch success rate across 2,100+ cGMP drug substance batches, holding 400+ regulatory approvals in 90+ countries. Celltrion recently acquired Eli Lilly's Branchburg, New Jersey facility and launched Celltrion BioSolutions as a dedicated CDMO subsidiary, with plans to expand DS capacity to 132,000L by 2030.
Frequently Asked Questions
What is the difference between API and drug product manufacturing?+
API (Active Pharmaceutical Ingredient) manufacturing produces the chemical compound that provides therapeutic effect. Drug product manufacturing takes that API and formulates it into the final dosage form patients receive -- tablets, capsules, injectables, creams, etc. Some CDMOs handle both; many specialize in one.
How do you choose a small molecule CDMO?+
Match your project stage to the CDMO's capabilities. Early-phase needs: strong process chemistry and flexibility. Late-phase needs: validated manufacturing, regulatory filing support, and commercial-scale capacity. Check their experience with your reaction types (hydrogenation, cryogenic, high-pressure) and any special handling requirements (potent, controlled substances).
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
